TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00792181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Course intervention - a professional development course for caregivers.
Description: The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Course intervention - a professional development course for caregivers.
Description: The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
Study: NCT04386902

Intervention type: DEVICE
Intervention: Neurosteer Aurora system
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
Study: NCT00659087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Block
Description: Those receiving femoral block postoperatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Those receiving only usual pain management postoperatively
Study: NCT01639352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOM230
Description: Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
Study: NCT04517292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin,cisplatin
Description: Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,cisplatin
Description: Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
Study: NCT02200146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Prednisone
Description: Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
Study: NCT04142333

Intervention type: GENETIC
Group type: OTHER
Intervention: GIA
Description: Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
Study: NCT03135314

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cocoa flavanol
Description: 7 days intake of cocoa flavanol supplement (naturex)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cocoa flavanol
Description: 7 days intake of cocoa flavanol supplement (naturex)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 days of placebo intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 days of placebo intake
Study: NCT02059837

Intervention type: PROCEDURE
Intervention: recurrent pterygium excision and following grafting
Description: The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
Study: NCT01219582

Intervention type: DRUG
Intervention: Glucobay M (Acarbose/Metformin, BAY81-9783)
Description: Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
Study: NCT03520452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green coffee extract
Description: Reconstituted in water and given to subjects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02006251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Instrumentation
Description: To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Total Hip Arthroplasty
Description: Total hip arthroplasty performed according to standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Total Hip Arthroplasty
Description: Total hip arthroplasty performed according to standard of care
Study: NCT02361268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialysis-yoga
Description: The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
Study: NCT05715385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser photocoagulation
Description: Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drop bromfenac 0.09%
Description: twice daily e/d bromfenac 0.09% for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
Study: NCT03307005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate
Description: Zolpidem tartrate 5 mg capsule one per night taken for 7 nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule one per night taken for 7 nights
Study: NCT01298687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00013%
Description: Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00033%
Description: Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.001%
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution, 0.00267%
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost Ophthalmic Solution, 0.004%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost Vehicle
Description: Inactive ingredients used as an active comparator
Study: NCT04488770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3882347
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided
Study: NCT04232839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation F2
Description: T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416 Formulation F2
Description: T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast.
Study: NCT04210986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Study: NCT02936973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real catgut implantation at acupoints
Description: 1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham catgut implantation at acupoints
Description: Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group.
Study: NCT04112576

Intervention type: DEVICE
Intervention: Wearable cardiac monitor
Description: Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
Study: NCT04488770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching strength placebo capsules will be provided
Study: NCT02781090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSFW+
Description: PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AHA
Description: The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: All participants, in both study arms, will be offered a 3-month supply of nicotine patches
Study: NCT00198276

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MedPulser Electroporation with bleomycin
Description: The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
Study: NCT01766115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: HCV Protease Inhibitor
Study: NCT03556904

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation Therapy
Description: Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy or chemotherapy
Description: Current standard of care dosing with standard agents; hormone therapy or chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy or chemotherapy
Description: Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
Study: NCT02074189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
Study: NCT02770612

Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed opioids
Description: Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
Study: NCT02562170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TiLoop Bra

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protexa
Study: NCT01653977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMIZED
Description: In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
Study: NCT02885558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efonidipine
Description: 8 weeks treatment with either efonidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: 8 weeks treatment with either nifedipine
Study: NCT02636725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
Study: NCT04042025

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Onasemnogene Abeparvovec-xioi
Description: Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Study: NCT00392925

Intervention type: DRUG
Group type: OTHER
Intervention: pramlintide acetate 360 mcg
Description: subcutaneous injection, twice a day, 360mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate 360 mcg
Description: subcutaneous injection, twice a day, 360mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate 360 mcg
Description: subcutaneous injection, twice a day, 360mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day, 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: subcutaneous injection, twice a day, 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-pramlintide 600 uL
Description: twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-metreleptin 1 mL
Description: twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Pramlintide acetate 180 mcg
Description: subcutaneous injection twice a day, 180 mcg